The Evening Versus Morning Polypill Utilization Study
Information source: UMC Utrecht
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiovascular Disease; Cerebrovascular Disease; Peripheral Arterial Disease
Intervention: Cardiovascular Agents (Drug)
Phase: N/A
Status: Completed
Sponsored by: UMC Utrecht Official(s) and/or principal investigator(s): W. Spiering, MD, PhD, Principal Investigator, Affiliation: UMC Utrecht
Summary
Background and rationale:
In clinical practice, antihypertensives are generally prescribed for use in the morning,
whereas some statins are recommended for use in the evening. There is evidence that the
reduction in LDL cholesterol achieved with some statins is superior when taken in the night,
but it is unclear whether the additional reduction in LDL cholesterol(and the reported
improvement in BP control when aspirin is taken in the evening) is offset by a reduction in
adherence when taking medication in the evening. Current product labelling recommends night
use for simvastatin and does not state a timing preference for aspirin or blood pressure
lowering medicines. There is therefore uncertainty concerning the best timing of
administration of the polypill. This uncertainty will be addressed by this trial.
Trial design:
Randomised, open label cross over trial (n=75) of the polypill in the morning compared with
the evening administration compared with individual agent administration (acetylsalicylic
acid and blood pressure lowering agents in the morning, and statin in the evening) in
individuals at high risk of cardiovascular disease. Patients will be recruited to the RHP 2c
(acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12. 5mg),
and will be randomly allocated to the sequence of time of administration.
Clinical Details
Official title: A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: LDL cholesterol (polypill evening vs polypill morning)Mean 24 hour ambulatory systolic BP (polypill evening vs morning)
Secondary outcome: Differences in ambulatory BP parameters after a mean of 7 week of treatment (polypill evening vs. morning, polypill vs regular care)Differences in tolerability (adverse event, cessation of treatment) Adherence (polypill evening vs. morning, polypill vs regular care) Cholesterol fractions (polypill evening vs. morning, polypill vs regular care)
Detailed description:
Background and rationale:
In clinical practice, antihypertensives are generally prescribed for use in the morning,
whereas some statins are recommended for use in the evening. There is evidence that the
reduction in LDL cholesterol achieved with some statins is superior when taken in the night,
but it is unclear whether the additional reduction in LDL cholesterol(and the reported
improvement in BP control when aspirin is taken in the evening) is offset by a reduction in
adherence when taking medication in the evening. Current product labelling recommends night
use for simvastatin and does not state a timing preference for aspirin or blood pressure
lowering medicines. There is therefore uncertainty concerning the best timing of
administration of the polypill. This uncertainty will be addressed by this trial.
Trial design:
Randomised, open label cross over trial (n=75) of the polypill in the morning compared with
the evening administration compared with individual agent administration (acetylsalicylic
acid and blood pressure lowering agents in the morning, and statin in the evening) in
individuals at high risk of cardiovascular disease. Patients will be recruited to the RHP 2c
(acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12. 5mg),
and will be randomly allocated to the sequence of time of administration.
Aim:
To measure whether there is a difference in LDL cholesterol levels or the 24 hour ambulatory
blood pressure in individuals at high risk of cardiovascular disease when the polypill is
taken in the morning compared to the evening.
Randomisation and trial treatment:
Eligible individuals willing to participate in the trial will receive the polypill for a
total of 18 weeks and be randomised to the sequence of 6 weeks morning, 6 weeks evening
administration and 6 weeks administration of the individual agents. The polypill will be
provided by the investigator at the Trial Centre. Participants will also receive information
about smoking cessation (if applicable) and how to follow a healthy heart diet. They will be
advised to increase physical activity and lose weight if needed.
Data collection and follow-up:
Participants will be followed-up for 20 weeks. Ambulatory blood pressure will be measured at
baseline and week 6, week 12 and week 18. Fasting lipids will be measured at baseline, weeks
6, 12 and 18. Tolerability will be assessed at weeks 6, 12, 18 and 20 as will adverse
events. Participant acceptability will be measured at the end of the treatment period.
Primary outcome:
Difference in LDL cholesterol and mean 24 hour ambulatory systolic BP.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- The participant is able to give informed consent.
- The trial Investigator considers that each of the polypill components are indicated
at the doses in the Red Heart Pill
- Established atherothrombotic cardiovascular disease (CVD) or intermediate to high
cardiovascular risk, defined as;
- History of coronary heart disease (myocardial infarction, stable or unstable
angina pectoris, or coronary revascularisation procedure), or
- History of ischaemic cerebrovascular disease (ischaemic stroke or transient
ischaemic attack), or
- History of peripheral vascular disease (peripheral revascularisation procedure
or amputation due to vascular disease or aortic reconstruction), or
- For individuals without established cardiovascular disease, a calculated 5 year
CVD risk of 5% or greater (calculated using the 1991 Anderson Framingham risk
equation with adjustments as defined by the New Zealand Guidelines Group
recommendations - (Appendix 1))
Exclusion Criteria:
- Contraindication to any of the components of the polypill (e. g. known intolerance to
aspirin, statins, or ACE inhibitors; pregnancy or likely to become pregnant or
breastfeeding women during the treatment period). Such contraindications are fully
listed in the Investigator Brochures.
- The treating doctor considers that changing a participant's cardiovascular
medications would put the participant at risk (e. g. symptomatic heart failure, high
dose β-blocker required to manage angina or for rate control in atrial fibrillation,
accelerated hypertension, severe renal insufficiency, a history of severe resistant
hypertension).
- Other potential reasons for exclusion include:
- Known situation where medication regimen might be altered for a significant length of
time, e. g. current acute cardiovascular event, planned coronary bypass graft
operation.
- Unlikely to complete the trial (e. g. life-threatening condition other than
cardiovascular disease) or adhere to the trial procedures or attend study visits
(e. g. major psychiatric condition, dementia).
- Any reason, medical condition, ongoing medication or significant disability that
would prevent the participant complying with trial consent, treatment and follow-up
procedures or potentially jeopardise her / his medical care.
- Night shift workers.
Locations and Contacts
UMC Utrecht, Utrecht 3508 GA, Netherlands
Additional Information
Starting date: July 2012
Last updated: August 12, 2013
|